The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 01, 2011
Filed:
Feb. 22, 2006
Yoshikazu Kurosawa, Nagoya, JP;
Yasushi Akahori, Nagoya, JP;
Nobuhiro Takahashi, Tokyo, JP;
Atsushi Sugioka, Nagoya, JP;
Nobuhiro Hayashi, Toyoake, JP;
Akihiko Takasaki, Nagoya, JP;
Kazuhiro Suzuki, Toyota, JP;
Miwa Morita, Toyoake, JP;
Gene Kurosawa, Nagoya, JP;
Sari Fujiyama, Tokyo, JP;
Susumu Tsustumi, Nagoya, JP;
Keiko Ogawa, Toyoake, JP;
Kazuki Matsuda, Nagoya, JP;
Chiho Muramatsu, Toyoake, JP;
Yoshitaka Iba, Nagoya, JP;
Mariko Sumitomo, Nagoya, JP;
Masachika Azuma, Nagoya, JP;
Yoshinori Ukai, Nagoya, JP;
Kazuhiro Morishita, Miyazaki, JP;
Yoshikazu Kurosawa, Nagoya, JP;
Yasushi Akahori, Nagoya, JP;
Nobuhiro Takahashi, Tokyo, JP;
Atsushi Sugioka, Nagoya, JP;
Nobuhiro Hayashi, Toyoake, JP;
Akihiko Takasaki, Nagoya, JP;
Kazuhiro Suzuki, Toyota, JP;
Miwa Morita, Toyoake, JP;
Gene Kurosawa, Nagoya, JP;
Sari Fujiyama, Tokyo, JP;
Susumu Tsustumi, Nagoya, JP;
Keiko Ogawa, Toyoake, JP;
Kazuki Matsuda, Nagoya, JP;
Chiho Muramatsu, Toyoake, JP;
Yoshitaka Iba, Nagoya, JP;
Mariko Sumitomo, Nagoya, JP;
Masachika Azuma, Nagoya, JP;
Yoshinori Ukai, Nagoya, JP;
Kazuhiro Morishita, Miyazaki, JP;
Institute for Antibodies Co., Ltd., Nagoya, JP;
Other;
Abstract
It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.